Invested in FinalDose, a programmable DNA-targeted drug platform aimed at previously undruggable cancer targets.
FinalDose is focused on developing a complete architecture for cancer therapy, utilizing DNA programmability to enhance treatment effectiveness
FinalDose is focused on developing a complete architecture for cancer therapy, utilizing DNA programmability to enhance treatment effectiveness.